Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1362197 | Bioorganic & Medicinal Chemistry Letters | 2011 | 5 Pages |
A series of furoxan-based nitric oxide-releasing chrysin derivatives were synthesized. Pharmacological assays indicated that all chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-product formation. Some chrysin derivatives were also found to increase the glucose consumption of HepG2 cells. Furthermore, the compounds released a low amount of NO in the presence of l-cysteine (range from 0.20% to 1.89%). These hybrid furoxan-based NO donor chrysin derivatives offer a mutual prodrug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.
Graphical abstractA group of hybrid furoxan based nitric oxide-releasing chrysin derivatives was synthesized. All these chrysin derivatives released NO upon incubation with PBS at pH 7.4, exhibited inhibitory activities against aldose reductase and advanced glycation end-products formation in vitro. And some of them were even found to increase the glucose consumption of HepG2 cells.Figure optionsDownload full-size imageDownload as PowerPoint slide